
    
      This is an experimental medical research study. The purpose of this study is to determine if
      Golimumab is safe and effective in the treatment of rheumatoid arthritis.

      Subjects will receive subcutaneous injections of either 50 or 100 mg Golimumab or placebo
      every two or four weeks or an infusion of infliximab at week 20, 22, 28, 36, 44 for 48 weeks
    
  